Following Biosimilar Trial, Jury Awards Amgen $70 Million for...


In one of the first Biologics Price Competition and Innovation Act litigations to reach trial, a jury on Friday awarded Amgen $70 million in damages for Pfizer's infringement of one of Amgen's expired patents protecting Epogen. Notably, the damages relate to product that Pfizer is not yet approved to sell in the United States.



from Biotech News